Tourmaline Bio to Present at Upcoming Investor Conferences
01 November 2023 - 1:00PM
Tourmaline Bio, Inc. (Nasdaq: TRML), a late-stage clinical
biotechnology company developing transformative medicines to
dramatically improve the lives of patients with life-altering
immune diseases, today announced that Sandeep Kulkarni, CEO, will
participate in the following investor conferences in November:
Guggenheim Healthcare 5th Annual I&I
Conference, New YorkFireside chatNovember 6, 2023 at 3:50
pm ET
Truist Securities BioPharma Symposium,
New York“Inflammatory Insights: Advancing Novel
Therapeutics Across I&I Indications” panel November 9, 2023 at
2:25 pm ET
Jefferies London Healthcare Conference,
LondonAvailable for one-on-one investor meetingsNovember
14 and 15, 2023
Piper Sandler 35th Annual Healthcare
Conference, New YorkFireside chatNovember 29, 2023 at 1:00
pm ET
Live webcasts and replays, if available, will be
made available under "Events and Presentations" in the News &
Investors section of the Tourmaline Bio website at
https://ir.tourmalinebio.com.
About Tourmaline Bio,
Inc.Tourmaline Bio is a late-stage clinical biotechnology
company driven by its mission to develop transformative medicines
that dramatically improve the lives of patients with life-altering
immune diseases. Tourmaline’s lead program, TOUR006, is an
anti-IL-6 antibody that exhibits differentiated properties
including high binding affinity to IL-6 and a naturally long
half-life. To date, TOUR006 has been studied in over 400 autoimmune
patients across six clinical trials. Tourmaline plans to develop
TOUR006 in thyroid eye disease (TED) and atherosclerotic
cardiovascular disease (ASCVD) as its first two indications, with
additional indications under consideration.
Contact:
Meru AdvisorsLee M. Sternlstern@meruadvisors.com
Tourmaline Bio (NASDAQ:TRML)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Tourmaline Bio (NASDAQ:TRML)
Historical Stock Chart
Von Jun 2023 bis Jun 2024